达格列净/艾塞那肽治疗2型糖尿病中血糖控制新调控机制的出现
研究纳入75例2型糖尿病患者,采用5小时双示踪口服葡萄糖耐量试验,比较达格列净、艾塞那肽及两药联合在急性期及治疗1、4个月后的血糖与内源性葡萄糖生成变化。结果显示,达格列净诱导的糖尿可刺激内源性葡萄糖生成,该机制独立于葡萄糖、胰岛素和胰高血糖素,且联合治疗较单药血糖控制更优。
要点
- 达格列净单药治疗时内源性葡萄糖生成下降幅度小于艾塞那肽单药。
- 达格列净/艾塞那肽联合治疗较单药血糖控制更优。
- 达格列净诱导的糖尿可刺激内源性葡萄糖生成,且不依赖胰岛素/胰高血糖素。
核心结论
- 研究提供强证据表明,达格列净诱导的糖尿可刺激2型糖尿病患者内源性葡萄糖生成,该机制持久且独立于葡萄糖、胰岛素和胰高血糖素。
- 达格列净联合GLP-1受体激动剂治疗较单药治疗血糖控制更优。
研究设计与样本
- 75例2型糖尿病患者接受5小时双示踪口服葡萄糖耐量试验(静脉3-(3H)-葡萄糖,口服(1-14C)-葡萄糖)。
- 急性研究:在达格列净、艾塞那肽或达格列净/艾塞那肽给药前及给药后1小时进行。
- 长期研究:在每种药物治疗1个月和4个月后进行。
主要发现
- 急性期口服葡萄糖耐量试验中,血糖升高幅度艾塞那肽组Δ=42±1 mg/dL低于达格列净组Δ=72±3 mg/dL,达格列净/艾塞那肽组Δ=11±3 mg/dL低于艾塞那肽组和达格列净组。
- 急性期内源性葡萄糖生成下降幅度达格列净组Δ=-0.65±0.03 mg/kg/min小于艾塞那肽组Δ=-0.96±0.07 mg/kg/min;达格列净/艾塞那肽组Δ=-0.84±0.05 mg/kg/min小于艾塞那肽组,大于达格列净组。
- 治疗1个月时,血糖升高幅度(艾塞那肽Δ=26±1 mg/dL,达格列净Δ=62±2 mg/dL,达格列净/艾塞那肽Δ=27±1 mg/dL)和内源性葡萄糖生成下降幅度(达格列净Δ=-0.60±0.05 mg/kg/min,艾塞那肽Δ=-0.77±0.04 mg/kg/min,达格列净/艾塞那肽Δ=-0.72±0.03 mg/kg/min)与急性期相似。
- 治疗4个月时,血糖升高幅度(艾塞那肽Δ=55±2 mg/dL,达格列净Δ=65±6 mg/dL,达格列净/艾塞那肽Δ=46±2 mg/dL)和内源性葡萄糖生成下降幅度(达格列净Δ=-0.66±0.04 mg/kg/min vs 艾塞那肽Δ=-0.84±0.05 mg/kg/min)也相似;达格列净/艾塞那肽组Δ=-0.65±0.03 mg/kg/min与达格列净组相等,小于艾塞那肽组。
- 血浆胰岛素/胰高血糖素变化不能解释达格列净/艾塞那肽组较艾塞那肽组更高的内源性葡萄糖生成。
临床怎么用
- 原文结论指出,达格列净联合GLP-1受体激动剂治疗较单药治疗血糖控制更优。
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: This study addresses the development of a new glucoregulatory mechanism in type 2 diabetes (T2D) patients treated with SGLT-2 inhibitors, which is independent of glucose, insulin and glucagon. The data suggest the presence of a potential trigger factor (s) arising in the kidney that stimulates endogenous glucose production (EGP) during sustained glycosuria. OBJECTIVE: To investigate effects of SGLT-2 inhibitor therapy together with GLP-1 receptor agonist on EGP and glucose kinetics in patients with T2D. Our hypothesis was that increased EGP in response to SGLT2i-induced glycosuria persists for a long period and is not abolished by GLP-1 RA stimulation of insulin secretion and glucagon suppression. METHODS: Seventy-five patients received a 5-hour dual-tracer oral glucose tolerance test (OGTT) (intravenous 3-(3H)-glucose oral (1-14C)-glucose): (1) before/after 1 of dapagliflozin (DAPA); exenatide (EXE), or both, DAPA/EXE (acute study), and (2) after 1 and 4 months of therapy with each drug. RESULTS: In the acute study, during the OGTT plasma glucose (PG) elevation was lower in EXE (Δ = 42 ± 1 mg/dL) than DAPA (Δ = 72 ± 3), and lower in DAPA/EXE (Δ = 11 ± 3) than EXE and DAPA. EGP decrease was lower in DAPA (Δ = -0.65 ± 0.03 mg/kg/min) than EXE (Δ = -0.96 ± 0.07); in DAPA/EXE (Δ = -0.84 ± 0.05) it was lower than EXE, higher than DAPA. At 1 month, similar PG elevations (EXE, Δ = 26 ± 1 mg/dL; DAPA, Δ = 62 ± 2, DAPA/EXE, Δ = 27 ± 1) and EGP decreases (DAPA, Δ = -0.60 ± 0.05 mg/kg/min; EXE, Δ = -0.77 ± 0.04; DAPA/EXE, Δ = -0.72 ± 0.03) were observed. At 4 months, PG elevations (EXE, Δ = 55 ± 2 mg/dL; DAPA, Δ = 65 ± 6; DAPA/EXE, Δ = 46 ± 2) and lower EGP decrease in DAPA (Δ = -0.66 ± 0.04 mg/kg/min) vs EXE (Δ = -0.84 ± 0.05) were also comparable; in DAPA/EXE (Δ = -0.65 ± 0.03) it was equal to DAPA and lower than EXE. Changes in plasma insulin/glucagon could not explain higher EGP in DAPA/EXE vs EXE mg/kg/min. CONCLUSION: Our findings provide strong evidence for the emergence of a new long-lasting, glucose-independent, insulin/glucagon-independent, glucoregulatory mechanism via which SGLT2i-induced glycosuria stimulates EGP in patients with T2D. SGLT2i plus GLP-1 receptor agonist combination therapy is accompanied by superior glycemic control vs monotherapy.
引用
- Cersosimo E, Alatrach M, Solis-Herrera C, et al. Emergence of a New Glucoregulatory Mechanism for Glycemic Control With Dapagliflozin/Exenatide Therapy in Type 2 Diabetes. J Clin Endocrinol Metab. 2023. PMID: 37481263. doi:10.1210/clinem/dgad438
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。